Sugi Predict

Sugi Predict / Compounds / SCHEMBL4008345

SCHEMBL4008345

SCHEMBL4008345

CS(=O)(=O)c1ccccc1S(=O)(=O)Nc1ccc2c(c1)c(I)nn2C(=O)O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 2/20 0.40
▸ MEN1 O00255 1/20 0.40
▸ LMNA P02545 1/20 0.40
▸ CYP1A2 P05177 1/20 0.40
▸ CYP3A4 P08684 1/20 0.40
▸ CYP2D6 P10635 1/20 0.40
▸ CYP2C9 P11712 1/20 0.40
▸ CYP2C19 P33261 1/20 0.40
▸ KMT2A Q03164 1/20 0.40
▸ TRIM24 O15164 1/20 0.38
▸ PKM P14618 1/20 0.38
▸ NR1I2 O75469 4/20 0.37
▸ ALDH1A1 P00352 1/20 0.37
▸ HTT P42858 1/20 0.37
▸ PFKFB3 Q16875 1/20 0.37
▸ PTGDR2 Q9Y5Y4 1/20 0.37
▸ BRD4 O60885 5/20 0.37
▸ BRD1 O95696 3/20 0.37
▸ BRPF1 P55201 3/20 0.37
▸ TP53 P04637 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4008201 0.87 NR1H2 (0.39) MAPTMEN1LMNACYP1A2CYP3A4
SCHEMBL4006726 0.83 MAPT (0.42) MAPTMEN1LMNACYP1A2CYP3A4
SCHEMBL4010828 0.75 NR1H2 (0.40) MAPTMEN1LMNACYP1A2CYP3A4
SCHEMBL6300196 0.72 NR1H2 (0.38) MAPTMEN1LMNACYP1A2CYP3A4
SCHEMBL6300200 0.72 NR1H2 (0.38) MAPTMEN1LMNACYP1A2CYP3A4
SCHEMBL4014485 0.72 HSD11B1 (0.31) BRD4TP53
SCHEMBL4006971 0.72 NR1H2 (0.38) MAPTMEN1LMNACYP1A2CYP3A4
SCHEMBL4006969 0.72 NR1H2 (0.38) MAPTMEN1LMNACYP1A2CYP3A4
SCHEMBL4007743 0.71 ITK (0.46) MEN1KMT2APKMBRD4
SCHEMBL4006966 0.70 NR1H2 (0.36) MAPTMEN1LMNACYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7473701-B2 Substituted indazoles, compositions containing them, method of production and use AVENTIS PHARMA S.A. (FR) 2009-01-06 — — US disclosed
US-20050059722-A1 Substituted indazoles, compositions containing them, method of production and use AVENTIS PHARMA S.A. (FR) 2005-03-17 — — US disclosed
US-6858638-B2 Substituted indazoles, compositions containing them, method of production and use AVENTIS PHARMA S.A. (FR) 2005-02-22 — — US disclosed
EP-1487803-A1 INDAZOLES SUBSTITUTED WITH AN ANTI-CANCEROUS ACTIVITY Aventis Pharma S.A. (FR) 2004-12-22 — — EP disclosed
US-20040106667-A1 Substituted indazoles, compositions containing them, method of production and use AVENTIS PHARMA S.A. (FR) 2004-06-03 — — US disclosed
WO-2003078402-A1 INDAZOLES SUBSTITUTED WITH AN ANTI-CANCEROUS ACTIVITY AVENTIS PHARMA S.A. (FR) 2003-09-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040106667-A1 Substituted indazoles, compositions containing them, method of production and use ABL1, CDK3, CILK1 MAPT 2426/4885MEN1 2247/4885LMNA 3903/4885
US-20050059722-A1 Substituted indazoles, compositions containing them, method of production and use ABL1, CDK3, CILK1 MAPT 3070/4885MEN1 2443/4885LMNA 4186/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.